Molecular News

Life Science Cares Launches in Switzerland

ZURICH, Switzerland, April 19, 2024 (GLOBE NEWSWIRE) -- Today, Life Science Cares, a collective effort of the life science industry to reduce the impact of poverty and inequality in their communities, launched in

GlobeNewswireApr 19 11:12 ET

Express News | Molecular Partners AG : JP Morgan Cuts Target Price to $4.10 From $4.50

Moomoo 24/7Apr 18 00:05 ET

Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 17, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein

GlobeNewswireApr 17 11:12 ET

Molecular Partners Publishes Invitation to Annual General Meeting 2024

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein

GlobeNewswireMar 26 09:26 ET

Earnings Call Summary | Molecular(MOLN.US) Q4 2023 Earnings Conference

The following is a summary of the Molecular Partners AG (MOLN) Q4 2023 Earnings Call Transcript:Financial Performance:Molecular Partners reported an annual revenue of CHF7 million for 2023, with CHF4

moomoo AIMar 15 11:26 ET · Conference Call

Express News | Molecular Partners FY 2023 GAAP EPS $(2.13) Misses $(2.00) Estimate, Sales $7.894M Beat $5.333M Estimate

Moomoo 24/7Mar 14 16:11 ET

Molecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor Presentations

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein

GlobeNewswireMar 1 16:00 ET

Molecular Partners Gears Up for 2024 Milestones, Including Data From Leukemia Treatment Trial

Molecular Partners (MOLN) late Sunday it is "on track to deliver" data in the first half of this year from the phase 1/2a trial of MP0533 as a potential treatment for patients with relapsed/refractory

MT NewswiresJan 8 14:39 ET

Molecular Partners Says Data From Projected Therapeutically Active Doses of MP0533 From Phase 1/2a Trial to Be Presented in H1

Seeking AlphaJan 8 11:34 ET

J.P. Morgan Event in Spotlight as Biotech M&A, Obesity Frenzy, AI Pick up

Seeking AlphaJan 7 12:00 ET

Molecular Partners, Orano to Collaborate on RDT Therapies for Cancer

Seeking AlphaJan 5 16:32 ET

Novocure Names Nicolas Leupin as Chief Medical Officer

Novocure (NVCR) said Thursday it appointed Nicolas Leupin as chief medical officer. Leupin previously served as chief medical officer at Molecular Partners (MOLN). Price: 13.51, Change: +0.01, Percent

MT NewswiresJan 4 16:52 ET

CALM, GLYC and RBBN Are Among After Hour Movers

Seeking AlphaJan 4 16:19 ET

NEXI, MTC and MOLN Among Pre-market Losers

Seeking AlphaJan 4 08:31 ET

12 Health Care Stocks Moving In Thursday's Pre-Market Session

GainersOmega Therapeutics (NASDAQ:OMGA) shares rose 110.6% to $5.75 during Thursday's pre-market session. The market value of their outstanding shares is at $317.0 million. Rapid Micro Biosystems (NAS

BenzingaJan 4 08:05 ET

12 Health Care Stocks Moving In Wednesday's After-Market Session

GainersPortage Biotech (NASDAQ:PRTG) shares moved upwards by 20.6% to $1.7 during Wednesday's after-market session. The company's market cap stands at $33.6 million. BIMI Intl Medical (NASDAQ:BIMI) st

BenzingaJan 3 16:31 ET

Molecular Partners to Present at 42nd Annual J.P. Morgan Healthcare Conference and Swiss Investor Conferences

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs

GlobeNewswireDec 14, 2023 01:00 ET

Molecular Partners Reports 'Encouraging' Initial Data From Phase 1/2a Trial of MP0533

Molecular Partners (MOLN) said Sunday that initial clinical data from its ongoing phase 1/2a trial of MP0533 as a potential treatment for patients with relapsed/refractory acute myeloid leukemia or my

MT NewswiresDec 11, 2023 05:07 ET

Molecular Partners Presented Initial Data From First Four Dosing Cohorts of Ongoing Phase 1/2a Trial Of MP0533 For Patients With Relapsed/Refractory AML And AML/MDS At 2023 ASH Meeting

Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today presented positive initial cl

BenzingaDec 10, 2023 12:51 ET

Catalyst Watch: Intel's AI Event, Oracle Earnings and CAVA IPO Lockup Expiration

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out.

Seeking AlphaDec 8, 2023 15:00 ET